We are pleased to share an interview with CEO Dr David Solomon following the acquisition of Sanmirna and how it transforms Thalia into a clinical stage RNS therapeutics business.
Your question will be sent privately to Thalia Therapeutics. The company may choose to make this question public.
Start the conversation
Ask Thalia Therapeutics a question about this update.
